Emily Kerns, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 164 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- Novo Nordisk$253
- Otsuka America Pharmaceutical, Inc.$231
- Amgen$205
- Dexcom, Inc.$190
- Teva Pharmaceuticals USA, Inc.$152
- plus $1K from 35 others
What the payments were for
- Food & beverage$2,902100%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $504 |
| Novo Nordisk | 16 | $253 |
| Otsuka America Pharmaceutical, Inc. | 12 | $231 |
| Amgen | 12 | $205 |
| Dexcom, Inc. | 8 | $190 |
| Teva Pharmaceuticals USA, Inc. | 7 | $152 |
| AstraZeneca | 8 | $129 |
| Lilly USA, LLC | 5 | $98 |
| Astellas Pharma US Inc | 3 | $76 |
| Abbott | 4 | $76 |
| Acadia Pharmaceuticals Inc | 4 | $76 |
| GSK | 5 | $71 |
| Viatris Specialty LLC | 3 | $68 |
| Merck | 4 | $59 |
| Novartis | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $58 |
| Lundbeck LLC | 3 | $52 |
| Pfizer | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $27 |
| Radius Health, Inc. | 1 | $26 |
| Vertex | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Bayer | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Sobi, Inc | 1 | $12 |
How this compares
$2,914 in reported general payments places this provider in the 80th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 25 | $20,220 |
| OzempicSemaglutide | 18 | $18,562 |
| EliquisApixaban | 11 | $12,584 |
| XareltoRivaroxaban | 13 | $7,288 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,901 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,284 |
| Dexlansoprazole DrDexlansoprazole | 16 | $2,600 |
| Gabapentin | 116 | $2,492 |
| Duloxetine Hcl | 60 | $1,433 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,384 |
| Levemir FlexpenInsulin Detemir | 12 | $1,318 |
| Potassium Chloride | 46 | $1,305 |
| Omeprazole | 88 | $1,219 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,198 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $129 | $26,12142 claims |
| Novo NordiskOzempic | $253 | $18,56218 claims |
| PfizerEliquis | $50 | $12,58411 claims |
| Johnson & JohnsonXarelto | $30 | $7,28813 claims |
| GSKBreo Ellipta | $71 | $4,28411 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $152 | $76112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 medical providers in Missouri.
Other medical in Macon
- Melanie ChisamSpringfield$92K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
- Dustin BartlettSpringfield$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Corey WhitesidesColumbia$15K
- David WinchellSaint Peters$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.